B01 Profiling of serum and plasma angiogenic biomarkers in breast cancer and colon cancer using Luminex xMAP technology-based human angiogenesis multiplex immunoassay panels. Wen-Rong Lie, EMD Millipore Corporation, St Charles, MO, United States.

B02 Ultrasound evaluation of anti-angiogenic therapy on patient-derived renal cell carcinoma xenograft tumors in the chicken embryo model. Matthew Lowerison, Robarts Research Institute, London, ON, Canada.

B03 The predictive value of microvessel density, vascular proliferation index and markers of VEGF associated angiogenesis in patients with metastatic melanoma treated with bevacizumab monotherapy. Cornelia Schuster, University of Bergen, Bergen, Norway.

B04 Tumor-associated macrophages support tumor angiogenesis via CXCL16 signaling in papillary thyroid carcinoma. Young Shin Song, Seoul National University College of Medicine, Seoul, Korea, Republic Of.

B05 An immune modulatory role for the Fes protein tyrosine kinase. Faizah Alotaibi, Queen's University, Kingston, Ontario, Canada.

B06 Targeting the immune microenvironment to improve colorectal cancer anti-angiogenic therapy. Keehoon Jung, Harvard Medical School, Boston, MA, United States.

B07, PR03 CXCR4 inhibition reverts immunosuppressive tumor microenvironment and facilitates anti-PD-1 immunotherapy in sorafenib-treated hepatocellular carcinoma. Rakesh Ramjiawan, Massachusetts General Hospital/Harvard Medical School, Charlestown, MA, United States.

B08, PR04 Intravital imaging of cytolytic activity reveals how poor tumor vascularization and hypoxia limit tumor rejection. Guy Shakhar, Weizmann Institute of Science, Rehovot, Israel.

B09 Nintedanib inhibits tumor and vessel growth and leads to vascular normalization in A549-NSCLC-xenografts. Maximilian Ackermann, Institute of Functional and Clinical Anatomy, Johannes Gutenberg-University Mainz, Germany.

B10 Effects of vascular normalization when combining miR-200b with radiation. Salma Azam, The University of North Carolina at Chapel Hill, Chapel Hill, NC, United States.


B12 Endothelial stabilizer SAC-1004 normalizes tumor vasculature and potentiates docetaxel chemotherapy in prostate cancer. Kyung Seok Han, Department of Urology ad Urological Science Institute, Yonsei University College of Medicine, Seoul, Korea, Republic Of.

B13 Hematopoietic stem cell-derived cancer-associated fibroblasts are novel contributors to the pro-tumorigenic microenvironment. Amanda LaRue, VAMC/Medical University of South Carolina, Charleston, SC, United States.
B14 Erlotinib-cisplatin combination inhibits growth and angiogenesis via c-MYC and HIF-1a in EGFR mutated lung cancer. Jasmine Lee, University of California, Davis, Davis, CA, United States.

B15 In Vivo Analysis of Repeated siRNA Silencing on Protein Expression Levels. Hamidreza Montazeri Aliabadi, Chapman University School of Pharmacy, Irvine, California, United States.

B16, PR01 CLIC3 is secreted by CAFs and enhances angiogenesis and tumor cell invasion by cooperating with TGM2. Sara Zanivan, CRUK Beatson Institute, Glasgow, United Kingdom.

B17 In-depth proteomics unveils fatty acid oxidation role in controlling vascular permeability. Francesca Patella, Cancer Research UK Beatson Institute, Glasgow, United Kingdom.

B18 Estrogen deficiency causes reawakening of dormant disseminated breast cancer cells via angiopoietin-1/Tie2 signaling. Hyun Ho Han, Yonsei University College of Medicine, Seoul, Korea, Republic Of.

B19 Anti-VEGF treatment normalizes tuberculosis granuloma vasculature and improves small molecule delivery. Meenal Datta, Massachusetts General Hospital and Harvard Medical School, Boston, MA, United States.


B21 Tertiary lymphoid organs within pancreatic ductal carcinoma tissue are a favorable prognosticator, being strongly associated with blood vessels not infiltrated by cancer cells. Nobuyoshi Hiraoka, National Cancer Center, Tokyo, Japan.

B22 Role of VEGFR-1 signaling in obesity-induced tumor progression. Joao Incio, MGH/Harvard Medical School, Boston, MA, United States.

B23 R-Ras inhibits autophosphorylation of VEGF receptor-2 in endothelial cells and suppresses the receptor activation in tumor vasculature. Sawada Junko, Sanford-Burnham Medical Research Institute, Orlando, FL, United States.


B25 R-Ras is critical for endothelial lumen formation, blood perfusion, and normalization of regenerating vasculature. Fangfei Li, Sanford-Burnham Medical Research Institute at Lake Nona, Orlando, FL, United States.

B26 Role of exosomal annexin a2 in angiogenesis and breast cancer metastasis. Sayantan Maji, University of North Texas Health Science Center, Fort Worth, TX, United States.
**Poster Session B**
March 7, 2015
4:00 p.m.–6:30 p.m.
Plaza International Ballroom D/E/F

**B27 Activin A induces vascular endothelial cell proliferation and angiogenesis in oral cancer.** Carine Oliveira, Piracicaba Dental School, University of Campinas, Piracicaba, Brazil.

**B28 Tumor-associated macrophages and angiogenesis in prostate cancer.** Pallavi Patil, Cleveland Clinic, Cleveland, OH, United States.